NCT04172779 2025-11-20
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
Clinical Trials
69 trialsNCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02961374 2022-07-26
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03086538 2022-06-15
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT03110484 2022-06-15
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Unknown
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT01210911 2021-04-21
GEM
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT00376948 2021-03-01
Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01222689 2020-07-31
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00313560 2020-06-04
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT02723578 2020-01-13
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Yonsei University
Phase 2 Completed
NCT00728000 2019-11-25
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Withdrawn
NCT00733746 2019-10-21
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00365144 2018-01-19
Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine
University of California, San Francisco
Phase 2 Completed
NCT00810719 2018-01-10
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
University of California, Davis
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT01693419 2017-08-23
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Hallym University Medical Center
Phase 2 Completed
NCT01729481 2017-07-19
ML22774
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT00841035 2017-05-19
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
Phase 2 Terminated
NCT00366457 2017-05-15
Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00550836 2017-04-05
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01108458 2017-03-03
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Stanford University
Phase 2 Terminated
NCT00470535 2017-02-23
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00336700 2016-09-19
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00696696 2016-06-30
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
NYU Langone Health
Phase 2 Completed
NCT00674973 2016-06-17
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01187901 2016-06-17
FAPEST
University of Utah
Phase 2 Completed
NCT00766636 2016-05-19
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00524121 2016-04-14
Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00532441 2016-02-12
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00461708 2015-10-15
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Hoffmann-La Roche
Phase 2 Completed
NCT00442507 2015-07-24
OSI3650
Washington University School of Medicine
Phase 2 Terminated
NCT00365391 2015-07-09
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01093222 2015-06-30
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00032110 2015-04-15
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01608841 2015-02-18
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
Taipei Veterans General Hospital, Taiwan
Phase 2 Unknown
NCT00652366 2015-02-11
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT01135498 2015-02-06
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00754494 2015-01-06
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00482625 2014-10-16
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00605722 2014-07-14
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
Hoffmann-La Roche
Phase 2 Completed